These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 33197478)

  • 1. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
    Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
    Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibody based therapeutics: Strengths and challenges.
    Thakur A; Huang M; Lum LG
    Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
    Acheampong DO
    Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
    Wei J; Yang Y; Wang G; Liu M
    Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
    Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
    Zhang T; Lin Y; Gao Q
    Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the study of CD47-based bispecific antibody in cancer immunotherapy.
    Zhang B; Li W; Fan D; Tian W; Zhou J; Ji Z; Song Y
    Immunology; 2022 Sep; 167(1):15-27. PubMed ID: 35575882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
    Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies.
    Swan D; Routledge D; Harrison S
    Br J Haematol; 2022 Feb; 196(3):488-506. PubMed ID: 34472091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China.
    Zhang Z; Luo F; Cao J; Lu F; Zhang Y; Ma Y; Zeng K; Zhang L; Zhao H
    J Hematol Oncol; 2021 Aug; 14(1):124. PubMed ID: 34399818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date.
    Zhao Q
    BioDrugs; 2020 Apr; 34(2):111-119. PubMed ID: 31916225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The promise of bispecific antibodies: Clinical applications and challenges.
    Lim SM; Pyo KH; Soo RA; Cho BC
    Cancer Treat Rev; 2021 Sep; 99():102240. PubMed ID: 34119803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
    Shim H
    Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
    Suurs FV; Lub-de Hooge MN; de Vries EGE; de Groot DJA
    Pharmacol Ther; 2019 Sep; 201():103-119. PubMed ID: 31028837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors.
    Hellmann MD; Bivi N; Calderon B; Shimizu T; Delafontaine B; Liu ZT; Szpurka AM; Copeland V; Hodi FS; Rottey S; Aftimos P; Piao Y; Gandhi L; Galvao VR; Leow CC; Doi T
    Clin Cancer Res; 2021 May; 27(10):2773-2781. PubMed ID: 33441294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
    Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
    J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibodies: design, therapy, perspectives.
    Sedykh SE; Prinz VV; Buneva VN; Nevinsky GA
    Drug Des Devel Ther; 2018; 12():195-208. PubMed ID: 29403265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts.
    Ghalamfarsa F; Khatami SH; Vakili O; Taheri-Anganeh M; Tajbakhsh A; Savardashtaki A; Fazli Y; Uonaki LR; Shabaninejad Z; Movahedpour A; Ghalamfarsa G
    Immunotherapy; 2021 Nov; 13(16):1355-1367. PubMed ID: 34641708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
    Lejeune M; Köse MC; Duray E; Einsele H; Beguin Y; Caers J
    Front Immunol; 2020; 11():762. PubMed ID: 32457743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.